A carregar...
Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis
Bevacizumab has demonstrated a survival benefit in patients with metastatic colorectal cancer (mCRC) when combined with chemotherapy. Several randomized clinical trials comparing the efficacy and toxicity of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) agains...
Na minha lista:
| Publicado no: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486826/ https://ncbi.nlm.nih.gov/pubmed/26171215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.572 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|